血液系统肿瘤二重癌26例临床分析  

作　　者：倪丽红 朱亭郡 涂燕 章敬成 何芳 胡慧仙 

机构地区：[1]浙江大学医学院附属金华医院,321000

出　　处：《浙江临床医学》2023年第3期380-382,共3页Zhejiang Clinical Medical Journal

基　　金：浙江省医药卫生科技计划项目(2020KY1006)。

摘　　要：目的探讨血液系统二重癌的发病因素、肿瘤分布情况及预后,早期识别疾病复发、转移、二重癌的发生,提高临床诊治水平。方法选取2014年4月至2021年7月本院收治的血液系统恶性肿瘤合并实体瘤的二重癌患者26例。结果其中第1癌为造血系统恶性肿瘤12例,包含2次癌均为造血系统恶性肿瘤7例。第1癌为实体瘤者共14例。第1癌为造血系统肿瘤与实体瘤相比,前者两次肿瘤的平均间隔时间更短,分别为10.6个月和48.7个月,且前者5年总体生存率低于后者,分别为54.5%和92.3%(P<0.05)。结论血液系统恶性肿瘤继发二重癌者预后差,早期诊断及治疗能改善患者生存。Objective To investigate the risk factors,tumor distribution and prognosis of dual cancer of the blood system,and to identify the recurrence,metastasis and occurrence of dual cancer in early stage,so as to improve the level of clinical diagnosis and treatment.Methods From April 2014 to July 2021,there were 26 patients developed hematological malignancies complicated with solid tumors simultaneously or successively.Results 12 cases of the first cancer were hematopoietic malignancies,including 7 cases both cancers were hematopoietic malignancies.The first carcinoma was solid tumor in 14 cases.Compared with solid tumors,the average interval between the first tumor and the second tumor was shorter,10.6 months and 48.7 months,respectively,and the 5-year overall survival rate of the former was lower than that of the latter,54.5%and 92.3%respectively(P<0.05).Conclusion The prognosis of patients with hematological malignancies secondary to dual cancer is poor.Early diagnosis and treatment can improve the survival of the patients.

关 键 词：血液系统肿瘤 二重癌 临床分析 

分 类 号：R730.4[医药卫生—肿瘤]